A1ZN34:BVMF
Astrazeneca Plc Bdr
139,90 R$
0,00%
(0,00) 1D
16 okt, 17:06:00 GMT-3 · BRL
search
Bütün simvollar
| Simvol | Qiymət | Dəyişiklik | % Dəyişiklik |
|---|
insights_autoA1ZN34 üçün ən vacib statistik məlumatlar yaradılır...
Açın
143,33 R$
Yüksək
143,33 R$
Aşağı
138,81 R$
Bazar kapitalizasiyası
259,42 mlrd
Ortalama həcm
892,00
Həcm
1,25K
52 həftəlik ən yüksək
190,40 R$
52 həftəlik ən aşağı
129,06 R$
Dövriyyədəki səhmlər
1,55 mlrd
İşçilərin sayı
96K
Açın
143,33 R$
Yüksək
143,33 R$
Aşağı
138,81 R$
Bazar kapitalizasiyası
259,42 mlrd
Ortalama həcm
892,00
Həcm
1,25K
52 həftəlik ən yüksək
190,40 R$
52 həftəlik ən aşağı
129,06 R$
Dövriyyədəki səhmlər
1,55 mlrd
İşçilərin sayı
96K
Xəbər materialları
Veb mənbələri və xəbər partnyorlarından
Yahoo Finance
·
12 saat öncə
Summit Therapeutics (SMMT) Stock Fair Value Edges Higher After AstraZeneca Deal And Trial Focus
Insider Monkey
·
1 gün öncə
AstraZeneca’s Shares Have Fallen, but Is 14.6x Forward Earnings a Buying Opportunity?
Traders Union
·
1 gün öncə
AstraZeneca shares technical analysis: Upward price move confirms strong near-term momentum
The Twelfth Magpie
·
1 gün öncə
While the market panics about the FTSE 100, Citi just raised its AstraZeneca target to £186
Profil
AstraZeneca plc is a Swedish–British multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.
The company was founded in 1999 through the merger of the Swedish Astra AB and the British Zeneca Group. Zeneca shareholders received 53.5% of the shares, while Astra shareholders received the remaining 46.5%. Its portfolio includes primary and speciality care, coverage for rare diseases, and a robust global presence across various regions. Since the merger it has been among the world's largest pharmaceutical companies and has made numerous corporate acquisitions, including Cambridge Antibody Technology, MedImmune, Spirogen and Definiens. It has its research and development concentrated in three strategic centres: Cambridge, England; Gothenburg, Sweden; and Gaithersburg, Maryland, US.
AstraZeneca traces its earliest corporate history to 1913, when Astra AB was formed by a large group of doctors and apothecaries in Södertälje. Wikipedia
Astrazeneca Plc Bdr haqqında
Baş İcraçı DirektorPascal Soriot
İşçilər96,1K
Təsis Tarixi6 apr 1999
Baş OfisKembric, Cambridgeshire, Birləşmiş Krallıq
SektorPharmaceutical industry
Veb-saytastrazeneca.com